Changes in Trypanosoma cruzi-specific immune responses after treatment: Surrogate markers of treatment efficacy

Clinical Infectious Diseases

Volumn 49, Issue 11, 2009, Pages 1675-1684

  Laucella, Susana A ^a   Mazliah, Damián Pérez ^a   Bertocchi, Graciela ^b   Alvarez, María G ^b   Cooley, Gretchen ^c   Viotti, Rodolfo ^b   Albareda, María C ^a   Lococo, Bruno ^b   Postan, Miriam ^a   Armenti, Alejandro ^b   Tarleton, Rick L ^c  

^a Instituto Nacional de Diagnostico e Investigacion de la Enfermedad de Chagas Dr Mario Fatala Chaben   (Argentina)

^b Hospital Interzonal General de Agudos Eva Peron   (Argentina)

^c UNIVERSITY OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZNIDAZOLE; GAMMA INTERFERON; INTERLEUKIN 2;

ADULT; ANTIBODY RESPONSE; ARTICLE; CHAGAS DISEASE; CHRONIC DISEASE; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE COURSE; ENZYME LINKED IMMUNOSPOT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MEMORY CELL; NONHUMAN; PARASITE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SERODIAGNOSIS; T LYMPHOCYTE; TREATMENT RESPONSE; TRYPANOSOMA CRUZI; TRYPANOSOMIASIS;

ADULT; CD8-POSITIVE T-LYMPHOCYTES; CHAGAS DISEASE; FLOW CYTOMETRY; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-2; MIDDLE AGED; NITROIMIDAZOLES; T-LYMPHOCYTES; TREATMENT OUTCOME; TRYPANOCIDAL AGENTS; TRYPANOSOMA CRUZI; YOUNG ADULT;

EID: 72849122497     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/648072     Document Type: Article

References (40)

1. Cancado JR. Tratamento especifico. In: Cancado JR, Chuster M, eds. Cardiopatía Chagásica. Belo Horizonte, Brazil: Fundacao Carlos Chagas, 1985:327-355
2. Fragata Filho AA, da Silva MA, Boainain E. Etiologic treatment of acute and chronic Chagas disease. Sao Paulo Med J 1995; 113:867-872
3. Sgambatti de Andrade AL, Zicker F, de Oliveira RM, et al. Randomized trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection. Lancet 1996; 348:1407-1413 (Pubitemid 26395235) (Pubitemid 26395235)
4. Sosa Estani S, Segura EL, Ruiz AM, Velásquez E, Porcel BM, Yampotis C. Efficacy of treatment with benznidazole in children. Am J TropMed Hyg 1998; 59:526-529
5. Viotti R, Vigliano C, Armenti H, Segura E. Treatment of chronic Chagas disease with benznidazole: clinical and serologic evolution of patients with longterm follow-up. Am Heart J 1994; 127:151-162 (Pubitemid 24040442) (Pubitemid 24040442)
6. Fabbro de Suasnábar D, Arias E, Streiger M, et al. Evolutive behavior towards cardiomyopathy of treated (nifurtimox or benznidazole) and untreated chronic chagasic patients. Rev Inst Med Trop Sao Paulo 2000; 42:99-109. (Pubitemid 30314521)
7. Viotti R, Vigliano C, Lococo B, et al. Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial. Ann Intern Med 2006; 144:724-734 (Pubitemid 46780632)
8. Fabbro DL, Streiger ML, Arias ED, Bizai ML, del Barco M, Amicone NA. Trypanocide treatment among adults with chronic Chagas disease living in Santa Fe city (Argentina), over a mean follow-up of 21 years: parasitological, serological and clinical evolution. Rev Soc Bras Med Trop 2007; 40:1-10.
9. Kaech SM, Hemby S, Kersh E, Ahmed R. Molecular and functional profiling of memory CD8 T cell differentiation. Cell 2002; 111:837-851 (Pubitemid 36106405) (Pubitemid 36106405)
10. Wherry EJ, Barber DL, Kaech SM, Blattman JN, Ahmed R. Antigenindependent memory CD8 T cells do not develop during chronic viral infection. Proc Natl Acad Sci 2004; 101:16004-16009 (Pubitemid 39507917) (Pubitemid 39507917)
11. Vezyz V, Masopust D, Kemball CC, et al. Continuous recruitment of naïve T cells contributes to heterogeneity of antiviral CD8 T cells during persistent infection. J Exp Med 2006; 203:2263-2269 (Pubitemid 44498361) (Pubitemid 44498361)
12. Shin H, Blackburn Shawn D, Blattman JN, Wherry EJ. Viral antigen and extensive division maintain virus-specific CD8 T cells during chronic infection. J Exp Med 2007; 204:941-949 (Pubitemid 46631621) (Pubitemid 46631621)
13. Moskophidis D, Lechner F, Pircher H, Zinkernagel RM. Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells. Nature 1993; 362:758-761 (Pubitemid 23125981) (Pubitemid 23125981)
14. Zajac AJ, Blattman JN, Murali-Krishna K, et al. Viral immune evasion due to persistence of activated T cells without effector function. J Exp Med 1998; 188:2205-2213 (Pubitemid 29028493) (Pubitemid 29028493)
15. Goepfert PA, Bansal A, Edwards BH, Ritter GD Jr, Tellez I. A significant number of human immunodeficiency virus epitope-specific cytotoxic T lymphocytes detected by tetramer binding do not produce gamma interferon. J Virol 2000; 74:10249-10255 (Pubitemid 30780838) (Pubitemid 30780838)
16. + T lymphocytes after infection with hepatitis C virus. J Virol 2001; 75:5550-5558
17. Kostense S, Vandenberghe K, Joling J, van Baarle D, Nanlohy N. Persistent numbers of tetramer+CD8+ T cells, but loss of interferon-gamma+ HIVspecific T cells during progression to AIDS. Blood 2002; 99:2505-2511
18. Wherry EJ, Blattman JN, Murali-Krishna K, van der Mos R, Ahmed R. Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J Virol 2003; 77:4911-4927 (Pubitemid 36402840) (Pubitemid 36402840)
19. elley-Gibbs DM, Dibble JP, Filipson S, HaynesL, Kemp RA, Swain SL. Repeated stimulation of CD4 effector T cells can limit their protective function. J Exp Med 2005; 201:1101-1112
20. Radziewicz H, Ibegbu CC, Fernandez ML, et al. Liver-infiltrating lymphocytes in chronic human hepatitis C virus infection display an exhausted phenotype with high levels of PD-1 and low levels of CD127 expression. J Virol 2007; 81:2545-2553 (Pubitemid 46447020) (Pubitemid 46447020)
21. + T cells specific for Trypanosoma cruzi in chronic Chagas disease. PLoS Negl Trop Dis 2008; 2:e288.
22. + T cells in chronic Chagas disease patients. Int Immunol 2006; 18:465-471
23. World Health Organization. Control of Chagas disease. World Health Organ Tech Rep Ser 1991; 811:1-95.
24. Kuschnir E, Sgammini H, Castro R, Evequoz C, Ledesma R, Brunetto J. Evaluation of cardiac function by radioisotopic angiography, in patients with chronic Chagas cardiopathy. Arq Bras Cardiol 1985; 45:249-256
25. Laucella SA, Postan M, Martín D, et al. The frequency of IFN-γ T cells specific for Trypanosoma cruzi inversely correlates with disease severity in chronic human Chagas disease. J Infect Dis 2004; 189:909-918 (Pubitemid 38328193) (Pubitemid 38328193)
26. Cooley G, Etheridge RD, Boehlke C, et al. High throughput selection of effective serodiagnostics for Trypanosoma cruzi infection. PLoS Negl Trop Dis 2008; 2:e316.
27. Andrade SG, Freitas LA, Peyrol S, Pimentel AR, Sadigursky M. Experimental chemotherapy of Trypanosoma cruzi infection: persistence of parasite antigens and positive serology in parasitologically cured mice. Bull World Health Organ 1991; 69:191-197
28. García S, Ramos CO, Senra JF, et al. Treatment with benznidazole during the chronic phase of experimental Chagas disease decreases cardiac alterations. Antimicrob Agents Chemother 2005; 49:1521-1528 (Pubitemid 40463384) (Pubitemid 40463384)
29. Macedo VO, Silveira CA. Perspectivas da terapeutica especifica na doenca de Chagas: experiencias na forma indeterminada. Rev Soc Bras Med Trop 1987; 20(Suppl 2):M24-6.
30. Lauria-Pires L, Braga MS, Vexenat AC, et al. Progressive chronic Chagas heart disease ten years after treatment with anti-Trypanosoma cruzi nitroderivatives. Am J Trop Med Hyg 2000; 63:111-118 (Pubitemid 32488345) (Pubitemid 32488345)
31. + T central memory response in chronic Chagas disease. Nat Med 2008; 14:542-550
32. Britto C, Silveira C, Cardoso MA, Marques P, Luquetti A, Macedo V. Parasite persistence in treated chagasic patients revealed by xenodiagnosis and polymerase chain reaction. Mem Inst Oswaldo Cruz 2001; 96:823-826 (Pubitemid 33639948)
33. Zulantay I, Honores P, Solari A, et al. Use of polymerase chain reaction (PCR) and hybridization assays to detect Trypanosoma cruzi in chronic chagasic patients treated with itraconazole or allopurinol. Diagn Microbiol Infect Dis 2004; 48:253-257 (Pubitemid 38519582) (Pubitemid 38519582)
34. Piron M, Fisa R, Casamitjana N, et al. Development of a real-time PCR assay for Trypanosoma cruzi detection in blood samples. Acta Trop 2007; 103:195-200. (Pubitemid 47307326) (Pubitemid 47307326)
35. Fernandez CD, Tiecher FM, Balbinot MM, Liarte DB, Scholl D, Steindel M, Romanha A. Efficacy of benznidazole treatment for asymptomatic chagasic patients from state of Rio Grande do Sul evaluated during a three-year follow-up. Mem Inst Oswaldo Cruz 2009; 104:27-32.
36. van Baarle D, Tsegaye A, Miedema F, Akbar A. Significance of senescente for virus-specific memory T cell responses: rapid ageing during chronic stimulation of the immune system. Immunol Lett 2005; 97: 19-29. (Pubitemid 40038851) (Pubitemid 40038851)
37. Gallerano RH, Marr JJ, Sosa RR. Therapeutic efficacy of allopurinol in patients with chronic Chagas disease. Am J Trop Med Hyg 1990; 43:159-166
38. Apt W, Arribada A, Zulantay I, Solari A, Sanchez G. Itraconazole or allopurinol in the treatment of chronic American trypanosomiasis: the results of clinical and parasitological examinations 11 years post-treatment. Ann Trop Med Parasitol 2005; 99:733-741 (Pubitemid 41695614) (Pubitemid 41695614)
39. Tarleton RL, Reithinger R, Urbina JA, Kitron U, Gürtler RE. The challenges of Chagas Disease-grim outlook or glimmer of hope. PLoSMed 2007; 4:e332.
40. Rassi A Jr, Dias JCP, Marin-Neto JA, Rassi A. Challenges and opportunities for primary, secondary, and tertiary prevention of Chagas disease. Heart 2009; 95:524-534